Oncimmune Current Deferred Revenue from 2010 to 2024

ONC Stock   14.75  0.05  0.34%   
Oncimmune Holdings' Current Deferred Revenue is increasing over the years with stable fluctuation. Current Deferred Revenue is expected to dwindle to about 167.6 K. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2010-12-31
Previous Quarter
176.4 K
Current Value
167.6 K
Quarterly Volatility
1.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Oncimmune Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncimmune Holdings' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 2.4 M or Selling General Administrative of 474.1 K, as well as many indicators such as . Oncimmune financial statements analysis is a perfect complement when working with Oncimmune Holdings Valuation or Volatility modules.
  
This module can also supplement various Oncimmune Holdings Technical models . Check out the analysis of Oncimmune Holdings Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Oncimmune Stock

Oncimmune Holdings financial ratios help investors to determine whether Oncimmune Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncimmune with respect to the benefits of owning Oncimmune Holdings security.